The essentials
France expands bronchiolitis prevention with approved antibodies and vaccines starting September 2026.
France is launching an expanded bronchiolitis prevention campaign beginning September 14, 2026, building on previous efforts that protected over 450,000 infants. The strategy incorporates multiple approved interventions: Enflonsia and Beyfortus monoclonal antibodies, along with the Abrysvo vaccine for pregnant women.
Beyfortus reduces RSV-related hospitalizations by approximately 80 percent, while Abrysvo protects infants against RSV for the first 6 months of life when administered to mothers during pregnancy. Synagis remains approved for high-risk infants. Both Beyfortus and Enflonsia are available in two different dosages to accommodate varying clinical needs.
The 2024-2025 bronchiolitis season in Auvergne-Rhône-Alpes demonstrated a moderate epidemic with reduced severity, informing the campaign's scope and approach.
Other ways to read this story.
Alternative framings generated by SigNews. These are not independent sources or attributed quotations.
France builds on proven prevention model with new tools
The September 2026 campaign represents an expansion of France's established bronchiolitis prevention framework, which previously protected over 450,000 infants. New therapeutic options—Beyfortus, Enflonsia, and Abrysvo—provide clinicians with multiple evidence-based interventions. The strategy reflects ongoing refinement of public health approaches to RSV prevention.
Multiple interventions target RSV prevention across age groups
The expanded strategy addresses bronchiolitis prevention through distinct mechanisms: monoclonal antibodies like Beyfortus (reducing hospitalizations by ~80%) target infants directly, while Abrysvo protects newborns through maternal vaccination. Synagis serves high-risk populations. Available dosage options enable tailored clinical decision-making across patient populations.